Idiopathic pulmonary fibrosis (IPF) is a chronic and often fatal pulmonary disorder. Conventional treatment with immunosuppressive therapy in IPF has been disappointing. The pathology of IPF demonstrates features of dysregulated/abnormal repair with exaggerated angiogenesis, fibroproliferation, and deposition of extracellular matrix, leading to progressive fibrosis and loss of lung function. The elucidation of mediators which orchestrate this aberrant tissue repair, as well as their longitudinal expression, will allow the development of novel interventions to treat this disorder. Interleukin-8 (IL-8), a member of the CXC chemokine family, has recently been shown to be a potent mediator of angiogenesis. In contrast, platelet factor 4 (PF4) and interferon gamma-inducible protein 10 (IP-10), related members of the CXC chemokine family, are angiostatic. We hypothesize that angiogenesis is an important process that contributes to the pathogenesis of pulmonary fibrosis, and that this neovascular response is dependent upon an imbalance of angiogenic vs angiostatic CXC chemokines. This paradigm predicts that the biological balance in the expression of these CXC chemokines dictates that angiogenesis in association with fibroproliferation either regresses or progresses to end-stage pulmonary fibrosis. In this proposal, we will focus on the role of angiogenic and angiostatic CXC chemokines and establish whether a biological imbalance in their expression favors the progression of pulmonary fibrosis. Our experimental strategy will address the following questions: l) Do specific cytokine networks exist during pulmonary fibrosis that shifts the biological balance in favor of angiogenic CXC chemokines? 2) Can gene transfer strategies induce a cytokine network that shifts the biological balance in favor of angiostatic CXC chemokines and reduce pulmonary fibrosis? 3) What is the cellular and molecular mechanism(s) that accounts for the disparity of IPF and control fibroblast production of angiogenic and angiostatic CXC chemokines? 4) Can angiostatic CXC chemokine gene transfer to human IPF pulmonary fibroblasts alter their phenotype and reestablish normal pulmonary fibroblast-like angiogenic activity. 5) Does an imbalance in angiogenic and angiostatic CXC chemokines, at baseline or in a temporal manner, correlate with various parameters of disease activity or response to therapy in IPF patients? BAL, lung tissue, and plasma will be obtained from IPF patients and control subjects. Pulmonary fibroblasts will be isolated from either IPF or control lung tissue. Bleomycin-induced murine lung fibrosis will serve as our in vivo experimental model of pulmonary fibrosis. Techniques employed in this application will include: Northern blot (or RT-PCR) and in situ hybridization analysis; cellular transfection; adenovirus-mediated CXC chemokine gene transfer, immunohistochemistry and ELISAs to determine cytokine production; bioassays for angiogenic activity; morphometric and FACS analyses of neovascularization and inflammation, in vivo depletion of CXC chemokines by passive immunization with neutralizing antibodies. The elucidation of the biology of angiogenic and angiostatic CXC chemokines in lPF will permit the development of novel and targeted therapy aimed specifically at attenuating pulmonary fibrosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL056402-04
Application #
6302442
Study Section
Project Start
1999-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
4
Fiscal Year
2000
Total Cost
$255,534
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Schmidt, S L; Nambiar, A M; Tayob, N et al. (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176-83
Trujillo, Glenda; Meneghin, Alessia; Flaherty, Kevin R et al. (2010) TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2:57ra82
Fell, Charlene D; Martinez, Fernando J; Liu, Lyrica X et al. (2010) Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181:832-7
Huang, Steven K; White, Eric S; Wettlaufer, Scott H et al. (2009) Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 23:4317-26
Fell, Charlene D; Liu, Lyrica Xiaohong; Motika, Caroline et al. (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:402-7
Huang, Steven K; Peters-Golden, Marc (2008) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133:1442-50
Han, M K; Murray, S; Fell, C D et al. (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183-8
Muro, Andres F; Moretti, Federico A; Moore, Bethany B et al. (2008) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177:638-45
Huang, Steven K; Wettlaufer, Scott H; Hogaboam, Cory M et al. (2008) Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med 177:66-74
Meneghin, A; Choi, E S; Evanoff, H L et al. (2008) TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol 130:979-92

Showing the most recent 10 out of 96 publications